RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Assessing the cost-effectiveness of the novavax COVID-19 vaccine as a potential booster vaccine option for adults in the United States
Paret, K., Beyhaghi, H., Herring, W., Rousculp, M., Toback, S., & Mauskopf, J. (2022). Assessing the cost-effectiveness of the novavax COVID-19 vaccine as a potential booster vaccine option for adults in the United States. Value in Health, 25(12), S89. Article EE184. https://doi.org/10.1016/j.jval.2022.09.434
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.
